177 related articles for article (PubMed ID: 36906878)
1. Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma.
Chen T; Zheng Y; Roskos L; Mager DE
J Pharmacokinet Pharmacodyn; 2023 Aug; 50(4):251-265. PubMed ID: 36906878
[TBL] [Abstract][Full Text] [Related]
2. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Sonpavde GP; Sternberg CN; Loriot Y; Marabelle A; Lee JL; Fléchon A; Roubaud G; Pouessel D; Zagonel V; Calabro F; Banna GL; Shin SJ; Vera-Badillo FE; Powles T; Hellmis E; Miranda PAP; Lima AR; Emeribe U; Oh SM; Hotte SJ
Eur J Cancer; 2022 Mar; 163():55-65. PubMed ID: 35042068
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
Gonçalves A; Marchand M; Chan P; Jin JY; Guedj J; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):68-78. PubMed ID: 37877248
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
6. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
Thibault C; Elaidi R; Vano YA; Rouabah M; Braychenko E; Helali I; Audenet F; Oudard S
Bull Cancer; 2020 Jun; 107(5S):eS8-eS15. PubMed ID: 32620213
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
8. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A; Smith DD; Cacciamani GE; Cole S; Shakir A; Sadeghi S; Vogelzang NJ; Quinn D; Gill PS; Gill IS
Clin Genitourin Cancer; 2020 Oct; 18(5):351-360.e3. PubMed ID: 32146152
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
O'Donnell PH; Arkenau HT; Sridhar SS; Ong M; Drakaki A; Spira AI; Zhang J; Gordon MS; Degboe AN; Gupta AK; Mukhopadhyay P; Huang W; Abdullah SE; Angra N; Roskos LK; Guo X; Friedlander T
Cancer; 2020 Jan; 126(2):432-443. PubMed ID: 31581306
[TBL] [Abstract][Full Text] [Related]
12. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
[TBL] [Abstract][Full Text] [Related]
13. A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.
Moe A; Liow E; Redfern A; Swarbrick N; Ferguson T; Davis ID; Hayne D
BJU Int; 2021 Oct; 128 Suppl 1():9-17. PubMed ID: 33960102
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
15. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
Sonpavde G; Pond GR; Rosenberg JE; Choueiri TK; Bellmunt J; Regazzi AM; Mullane SA; Necchi A; Raggi D; Lee JL; Lee S; Simpson J; Derleth CL; Lin SW; Bajorin DF
Clin Genitourin Cancer; 2018 Aug; 16(4):e961-e967. PubMed ID: 29706503
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
[TBL] [Abstract][Full Text] [Related]
18. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
Aragaki AK; Jing Y; Hoffman-Censits J; Choi W; Hahn NM; Trock BJ; McConkey DJ; Johnson BA
Eur Urol Oncol; 2022 Jun; 5(3):338-346. PubMed ID: 34426176
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
[TBL] [Abstract][Full Text] [Related]
20. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
